Centre Leon Berard

27 trials 17 recruiting Academic / non-commercial

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

17 Recruiting

10 Completed trials

13 Countries active

44 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 4 Phase II/III: 1 Phase II: 14 Phase I/II: 8

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Ependymoma 1 Soft tissue sarcoma 1 Sarcoma 1 Metastatic renal cell carcinoma 1 Gastric cancer 1

Top IMPs

ATEZOLIZUMAB 3 CISPLATIN 2 DURVALUMAB 2 NIVOLUMAB 2 PEMBROLIZUMAB 2 ANASTROZOLE 1 BALSTILIMAB 1 BOTENSILIMAB 1 COBIMETINIB 1 CYCLOPHOSPHAMIDE 1 DOSTARLIMAB 1 ETOPOSIDE 1

All trials — page 2

27 total

ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati… Ended

2023-509227-41-00 Phase II 1 country
Trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer Ended

2024-516558-24-00 Phase II 1 country SARUPARIB
Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre… Ended

2024-516724-33-00 Phase I/II 1 country

Showing 25–27 of 27 trials

← All sponsors A–Z